Guardant Health Receives European Approval Of Guardant360 CDx As Companion Diagnostic For AstraZeneca’s ETCAMAH

Guardant Health has received European approval for its Guardant360 CDx as a companion diagnostic for AstraZeneca’s ETCAMAH, enabling earlier identification of cancer mutations and improved patient outcomes. This approval represents the 31st companion diagnostic approval for Guardant Health. The development is expected to enhance the company's presence in major global markets.